CellChorus

Executive Summary

CellChorus is a Houston-based private company founded in 2019 that pioneers dynamic single-cell analysis at scale through its proprietary TIMING (Time-lapse Imaging Microscopy in Nanowell Grids) platform. By combining high-throughput nanowell imaging with visual AI, CellChorus enables real-time observation and quantification of individual cell behaviors—such as migration, proliferation, and response to stimuli—across thousands of cells simultaneously. This approach addresses a critical bottleneck in biomedical research and drug development, where bulk assays mask heterogeneous cell responses. The TIMING platform offers unprecedented resolution in understanding cellular dynamics, with applications spanning oncology, immunotherapy, and regenerative medicine. CellChorus's technology stands out for its ability to generate rich phenotypic data that can accelerate target discovery, drug screening, and cell therapy optimization. While still at an early stage with no disclosed funding or valuation, the company is well-positioned to capitalize on the growing demand for single-cell analytics powered by artificial intelligence. Its Houston location provides access to the Texas Medical Center, a hub for translational research. Near-term catalysts include potential partnerships with pharmaceutical companies, a Series A funding round, and broader commercial rollout of the TIMING platform. If successful, CellChorus could become a key enabler of precision medicine by bridging the gap between single-cell genomics and functional cellular behavior.

Upcoming Catalysts (preview)

• Q4 2026Strategic partnership with a major pharmaceutical company for drug screening60% success
• Q3 2026Series A funding round70% success
• Q1 2027Launch of commercial TIMING platform for academic researchers50% success